Shares for Arena Pharmaceuticals fell 8% in early trading today as investors showed concern over the latest news about obesity drug Belviq. Arena announced that it received the Day 180 List of Outstanding Issues from the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP.
What it means
Arena's statement released today said that CHMP's "major objections relate to previously identified non-clinical and clinical issues, including tumors in rats, valvulopathy and psychiatric events." The company added that it would need to "further justify Belviq's overall benefit-risk balance taking these issues into consideration."
Let's examine each major objection one by one. Regarding tumors in rats, earlier clinical studies did find that the occurrence of malignant tumors increased in female rats taking dosages of Belviq that equate to 87 times the daily human dose. Occurrence of tumors in male rats increased at dosages of 17 times the daily human dose. Arena's public remarks about are that the relevance of these findings to human usage of Belviq are "unknown."
Regarding valvulopathy, or heart valve disorders, Arena's clinical studies found that 2.4% of patients developed valvular regurgitation, which is the backward flow of blood across a heart valve, after one year of taking Belviq. That amount compared to 2% of patients taking placebo who developed valvular regurgitation.
As for the concern about psychiatric events, some patients taking Belviq in clinical trials experienced euphoria, hallucination, and dissociation. Adverse reactions related to psychiatric disorders that required hospitalization or withdrawing from use of Belviq occurred in 2.2% of patients, compared with 1.1% of patients on placebo.
The issues about tumors in rats and valvulopathy were raised by CHMP in its 120-day list of questions. Arena responded to those questions, but apparently its responses weren't enough to satisfy the European regulators.Now, CHMP has added another concern.
While these concerns didn't prevent Belviq from gaining approval from the Food and Drug Administration in the U.S., European approval can be a steeper hill to climb. VIVUS also gained FDA approval for its diet drug Qsymia but received a negative recommendation from CHMP. Arena knew going in that Europe could be a challenge.
Granted, all of this doesn't necessarily mean that Belviq won't gain approval in Europe. It could. However, the latest news from Arena doesn't inspire any confidence. At this point, it appears that a negative recommendation from CHMP will be more likely than not. Based on this outlook, Arena's shares probably will remain depressed for the immediate future.
When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals gained FDA approval, but there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
The article Arena Shares Drop on European Questions originally appeared on Fool.com.
Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.